Market news

Smart Beta ETF report for RPV

PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk.

IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.

Smart Beta ETF report for RSPH

Smart Beta ETF report for RSPF

Smart Beta ETF report for RSPU

Active management and concentrated bets drove a 42% one-year return, though the lower-cost Invesco alternative offers broader diversification across 60 healthcare stocks.

RSPH levels the playing field across 60 established healthcare names while IBBQ bets on more than 250 biotech companies at a lower cost.

One fund targets pharma exclusively and surged 63% in a year, while the other diversifies across healthcare with lower volatility.

Moderna starts Phase 1 trials for Ebola vaccine mRNA-1469. See premarket MRNA stock reaction, analyst updates, and ETF exposure.

Smart Beta ETF report for RSP

FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.

IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.

RSPH offers 60 diversified holdings with lower volatility, while BBH concentrates on 25 biotech leaders with stronger recent returns.